EGFR and head and neck squamous cell carcinoma: In addition, NK cell–mediated ADCC is also exploited in the treatment of various cancers, and is enhanced in patients with HNSCC after treatment with cetuximab, the only clinically approved EGFR-targeted therapy (47).